Literature DB >> 22614781

Association of stem cell marker expression pattern and survival in human biliary tract cancer.

Ralf Kemmerling1, Beate Alinger, Otto Dietze, Hans-Christian Bösmüller, Matthias Ocker, Gernot W Wolkersdörfer, Frieder Berr, Daniel Neureiter, Tobias Kiesslich.   

Abstract

The aim of this study was to investigate the molecular and protein expression pattern of markers of stemness phenotype and its clinicopathological significance in human biliary tract cancer (BTC). Human BTC cell lines (CCLP-1, Egi-1, MzChA-1, MzChA-2, SkChA-1, TFK-1 and GBC) were analyzed in vitro and in xenotransplanted animals for expression of markers of stemness and compared to tissue microarrays (TMA) of 34 cases of human BTC with complete pathomorphological and clinical data (survival). Molecular analyses on the mRNA and protein level included makers of stemness and progenitor (Bmi-1, Sox-2, Nestin, CD133, CD44 and Nanog), proliferation and differentiation (cell cycle proteins, intermediate filaments). The investigated BTC samples showed a low to moderate and partially significantly different expression pattern of the stem cell markers in vitro, in vivo and in TMA. Hierarchical cluster analysis identified subgroups with homogenous expression of stem cell markers significantly differing with respect to cytokeratin expression in xenografts and Ki67 proliferation marker in human TMA, respectively - thus indicating possible heterogeneous carcinogenesis pathways in BTC. Additionally, these stem cell markers could be linked to morphology and molecular markers of proliferation and differentiation on the mRNA and protein level. Finally, survival analysis identified the combination of CD133 and CD44 as an independent prognostic factor yet their value as prognostic factors need testing in prospective study design.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614781     DOI: 10.3892/ijo.2012.1477

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

Authors:  Eckhard Klieser; Maximilian Pichelstorfer; Denis Weyland; Ralf Kemmerling; Stefan Swierczynski; Adam Dinnewitzer; Tarkan Jäger; Tobias Kiesslich; Daniel Neureiter; Romana Illig
Journal:  Mol Clin Oncol       Date:  2016-03-11

2.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 3.  Single cell biology beyond the era of antibodies: relevance, challenges, and promises in biomedical research.

Authors:  Parvin Abraham; Tessy Thomas Maliekal
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

4.  MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines.

Authors:  Andrej Wagner; Christian Mayr; Doris Bach; Romana Illig; Kristjan Plaetzer; Frieder Berr; Martin Pichler; Daniel Neureiter; Tobias Kiesslich
Journal:  Int J Mol Sci       Date:  2014-11-05       Impact factor: 5.923

5.  The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

Authors:  Christian Mayr; Andrej Wagner; Magdalena Loeffelberger; Daniela Bruckner; Martin Jakab; Frieder Berr; Pietro Di Fazio; Matthias Ocker; Daniel Neureiter; Martin Pichler; Tobias Kiesslich
Journal:  Oncotarget       Date:  2016-01-05

Review 6.  Biliary tract cancer stem cells - translational options and challenges.

Authors:  Christian Mayr; Matthias Ocker; Markus Ritter; Martin Pichler; Daniel Neureiter; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

7.  Significance of stem cell marker Nanog gene in the diagnosis and prognosis of lung cancer.

Authors:  Zeng Liu; Jing Zhang; Honggang Kang; Guiming Sun; Baozhong Wang; Yanwen Wang; Mengxiang Yang
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

Review 8.  Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review.

Authors:  Dino Bekric; Daniel Neureiter; Markus Ritter; Martin Jakab; Martin Gaisberger; Martin Pichler; Tobias Kiesslich; Christian Mayr
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

9.  HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors.

Authors:  Eckhard Klieser; Romana Urbas; Stefan Swierczynski; Stefan Stättner; Florian Primavesi; Tarkan Jäger; Christian Mayr; Tobias Kiesslich; Pietro Di Fazio; Katharina Helm; Daniel Neureiter
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923

10.  lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.

Authors:  Gongcai Qiu; Donglai Ma; Fujun Li; Dongsheng Sun; Zhaolin Zeng
Journal:  Int J Oncol       Date:  2019-05-06       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.